Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi, and parasites change when they are exposed to antimicrobial drugs. Antibiotic drugs include antibiotics, antifungals, antivirals, antimalarials, and anthelmintic.
According to MRFR analysis, the global Antibiotic Resistance Market is expected to register a CAGR of 5.8% during the forecast period of 2019 to 2025 and was valued at USD 8,120 million in 2018.
The growth of global antibiotic resistance market is driven by various factors such as -Rising antibiotic drug resistance infections, rise in the incidence of chronic and infectious disease, increase in clinical developments of antibiotic resistance, and rise in global initiatives to control drug-resistance.
Several market players currently dominate the global antibiotic resistance market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.
• MELINTA THERAPEUTICS
• Nabriva Therapeutics plc
• PARATEK therapeutics
• Seres Therapeutics
• Theravance Biopharma
• Tetraphase Pharmaceuticals
• Basilea Pharmaceutica Ltd
• Entasis Therapeutics
• NEMESIS BIOSCIENCE LTD
• Procarta Biosystems
• Allecra Therapeutics
• The global antibiotic resistance market has been segmented based on drug class, disease, pathogen, and end user.
• The market, based on drug class, has been divided into cephalosporins, Combination therapies, tetracyclines, lipoglycopeptides, oxazolidinones, and others. The combination therapies segment is likely to be the largest growth during the review period due to the increased usage of these therapies for gram-negative infections.
• The global antibiotic resistance market has been bifurcated, based on disease, into complicated urinary tract infections, bloodstream infections, complicated intra-abdominal infections, clostridium difficile infections, acute bacterial and skin structure infections, hospital-acquired bacterial pneumonia/ventilator, community-acquired bacterial pneumonia, and others.
• The global antibiotic resistance market has been segmented based on pathogen into staphylococcus aureus, streptococcus pneumoniae, acinetobacter, enterococcus, Hemophilus influenzae, pseudomonas aeruginosa, clostridium difficile, K. pneumoniae, campylobacter, and others.
• The end user segment of the antibiotic resistance market includes hospitals & clinics, research organizations, and others.
Americas: The largest regional market owing to the increasing prevalence of infectious diseases would drive the growth of the antibiotic resistance market in this region.
North America: The North American market for antibiotic resistance is growing due to the increasing prevalence of infectious diseases such as pneumonia, urinary tract infections (UTI), and others, which would increase the usage of antibiotic resistance drugs within the region.
US: There is an increase in drug launches as well as drug approvals, which would drive the growth of the market in this country. For instance, Melinta Therapeutics (US), in June 2019, announced the US Food and Drug Administration (FDA) of supplemental new drug application for BAXDELA (delafloxacin) for the treatment of community-acquired bacterial pneumonia.
Canada: Increase in drug-resistant infections is projected to drive the growth of the antibiotic resistance market in this country. For instance, according to a recent projection by the Organization for Economic Co-operation and Development (OECD) by 2050, drug-resistant infections are predicted to lead an estimated 2.4 million excess deaths in developed countries, which includes nations like Canada, Australia, the U.S., and the UK.
Latin America: Rise in pneumococcal disease in Latin America is most noticeable in children aged less than six years. Moreover, the increasing rate of resistance of Streptococcus pneumoniae to penicillin and other antibiotics is expected to fuel the market growth in this region.
Europe: In 2016, antimicrobial resistance remained a serious threat to public health in Europe. Each year in the European Union, an estimated 25,000 patients die due to serious resistant bacterial infections acquired in hospitals. As a result, rise in infectious disease would drive the growth of market in this region.
UK: By 2050, drug-resistant infections are predicted to have an estimated 2.4 million excess deaths in developed countries such as the UK. Moreover, increasing infectious disease would drive the growth of the antibiotic resistance market in the UK.
Germany: In Germany, an estimated 400,000 to 600,000 patients suffer hospital-acquired infections every year, and about 10,000 to 15,000 of them die. Thus, rise in hospital-acquired infection would drive the market growth in this country.